release of gastrointestinal hormones has been reported to modulate reflex cardiovascular responses caused by gastric distension, although the role played by gastrin 17 is as yet unknown. The present study was therefore planned to determine the primary in vivo effect of gastrin 17 on coronary blood flow and cardiac function and the involvement of autonomic nervous system, CCK1/2 receptors, and nitric oxide (NO). In 40 anesthetized pigs, gastrin 17 was infused into the left anterior descending coronary artery at constant heart rate and arterial blood pressure. In 35 of the 40 pigs, the mechanisms of the observed hemodynamic responses were analyzed by repeating gastrin 17 infusion after autonomic nervous system and NO blockade, and after specific CCK receptors agonists/antagonists administration. Intracoronary gastrin 17 administration caused dose-related increases of both coronary blood flow and cardiac function. The intracoronary coadministration of CCK33/pentagastrin and gastrin 17 potentiated the coronary effects observed when the above agents were given alone (P Ͻ0.05). The potentiation of the cardiac response was observed only with the co-administration of pentagastrin and gastrin 17 (P Ͻ0.05). Moreover, blockade of muscarinic cholinoceptors (intravenous atropine) and of ␣-adrenoceptors (intravenous phentolamine) did not abolish the hemodynamic responses to gastrin 17. The cardiac and vascular effects of the hormone were prevented by blockade of ␤-adrenoceptors (intravenous atenolol and butoxamine), CCK1/2 receptors (intracoronary lorglumide and CAM-1028), and NO synthase (intracoronary N-nitro-L-arginine methyl ester). In conclusion, gastrin 17 primarily increased coronary blood flow and cardiac function through the involvement of CCK receptors, ␤-adrenoceptors, and NO release.
adrenoceptors; coronary; gastrin; heart; nitric oxide DISTENSION OF HOLLOW VISCERA has been shown to stimulate mechanoreceptors located in their walls (5, 13, 21) . Such stimulation in anesthetized animals causes reflex responses that involve the cardiovascular system (25) . For instance, innocuous gastric distension in anesthetized pigs has been shown to cause reflex increases of arterial pressure and heart rate (41) and a decrease of coronary blood flow (40) mediated by sympathetic mechanisms and by activation of the renin-angiotensin system (30) . It is noteworthy that, in addition to exerting reflex cardiovascular effects, distension of the stomach is also involved in the secretion of gastrointestinal hormones, such as gastrin, through both local reflex neural mechanisms and modulation of the function of endocrine cells (18) . Food ingestionrelated release of gastrointestinal hormones into the circulation has been reported to modulate the cardiovascular responses to food intake and gastric distension (2, 27) . Some of these responses would thus be expected to influence the postprandial increase of cardiac output and of blood flow to the gastrointestinal organs through their cardiac chronotropic and inotropic effects and vasoactive properties (1, 14, 17) .
These cardiovascular effects have been variably related to both sympathetic mechanisms and the involvement of CCK1 and 2 receptors. For instance, intravenous administration of sulphated CCK8 in rats produced dose-dependent increases in arterial blood pressure through activation of ␣ adrenoceptors and the involvement of CCK1 receptors (8) . Similar results have been obtained with intravenous administration of CCK33, a CCK1 receptor agonist, which also increased cardiac function, reduced coronary blood flow, and caused tachycardia (47) . Moreover, both CCK8 and gastrin have been reported to cause dose-dependent increase of gastric mucosal blood flow through CCK1 and/or CCK2 receptors (8, 15) . Also, the infusion of the CCK2 receptor agonist pentagastrin has been found to cause variable effects on arterial blood pressure and to increase myocardial contractility and blood flow in the coronary, mesenteric, and gastric mucosal vascular beds (46, 32) . In this context, it is of interest that the increase of gastric mucosal blood flow in response to both gastrin and pentagastrin has also been found to be related to nitric oxide (NO) release (38, 33, 23, 44) .
Although there have been reported data on the hemodynamic effects elicited by gastrointestinal hormones, it remains unknown whether gastrin can directly affect cardiac function and coronary blood flow. However, the reported data raise the hypothesis that gastrin can increase both myocardial inotropism and cardiac perfusion through interaction with CCK receptors and modulation of cholinergic and adrenergic cardiovascular tone and NO release. The present work was therefore planned, in controlled experiments performed in anesthetized pigs, to investigate the primary in vivo effects of the administration of gastrin 17 on coronary blood flow and related myocardial function and the involvement of autonomic nervous system, CCK receptors, and NO.
MATERIALS AND METHODS
The experiments were carried out in 40 domestic pigs, weighing 65-70 kg, supplied by an accredited dealer (Azienda Agricola Invernizzi, Olengo, Novara, Italy). The animals, fasted overnight, were anesthetized with intramuscular ketamine (20 mg/kg, Parke-Davis, Detroit, MI), followed after ϳ15 min by intravenous pentobarbitone sodium (15 mg/kg, Siegfried, Zofingen, Switzerland), and artificially ventilated with oxygen-enriched air using a respiratory pump (Harvard 613; Harvard Apparatus, South Natick, MA). Anesthesia was maintained throughout the experiments by continuous intravenous infusion of pentobarbitone sodium (7 mg·kg Ϫ1 ·h Ϫ1 ) and assessed as previously reported (24) from responses of the animals to somatic stimuli. The experiments were carried out in accordance with the national guidelines (DLGS 27/01/1992, licence no. 116) with the Institute for Laboratory Animal Research (National Research Council, Guide for the Care and Use of Laboratory Animals, Washington, DC: National Academy Press, 1996) and approved by our local review board. Pressures in the ascending aorta and right atrium were recorded via catheters connected to pressure transducers (Statham P23 XL; Gould, Valley View, OH) inserted into the right femoral artery and the right external jugular vein, respectively. The chest was opened in the left fourth intercostal space, the pericardium was cut, and an ultrasound flowmeter probe (model 420; Transonic Systems, Ithaca, NY) was positioned around the proximal part of the anterior descending coronary artery (LAD) to record coronary blood flow. Left ventricular pressure was measured by means of a catheter connected to a pressure transducer (Gould) inserted through the left atrium. The frequency response of the catheter-manometer system was found to be flat (Ϯ5%) up to 40 Hz. To pace the heart, electrodes were sewn on the left atrial appendage and connected to a stimulator (model S8800; Grass Instruments, Quincy, MA), which delivered pulses of 3-5 V for 2-ms duration at the required frequency. To assess regional contractile function, pairs of 2-mm ultrasonic segment length microtransducer crystals (Sonometrics, London, Ontario, Canada) were implanted in the left anterior ventricular wall in the distribution area of the LAD. Two additional crystals were placed at opposite ends of the short axis of the left ventricle to measure changes in ventricular dimension throughout cardiac cycles. Each pair of crystals was implanted in the midmyocardial layer ϳ10 mm apart and parallel to the direction of the fibers so that the segmental shortening was in line with the orientation of fibers (10, 12) .
Arterial blood samples were used to measure pH, arterial PO2 and PCO 2 (with a gas analyzer; Radiometer ABL505, Copenhagen, Denmark), and the hematocrit. Sampling of blood from LAD and the coronary venous sinus allowed the measurement of coronary artery and coronary venous PO2 and arterio-venous sinus oxygen content. The acid-base status of the animals was kept within normal limits as previously reported (24) . Infusions into the LAD were performed using a catheter connected to a butterfly needle inserted into the artery distal to the flowmeter probe. To prevent changes of arterial blood pressure, a pressurized reservoir connected to the arterial system of the animal was used as previously described (10 -12) . Coagulation of the blood was avoided by the intravenous injection of heparin (Parke Davis; initial doses of 500 IU/kg and subsequent doses of 50 IU/kg every 30 min). The rectal temperature of the pigs was monitored and kept between 38 and 40°C using an electric pad. Mean and phasic aortic blood pressure, mean right atrial pressure, left ventricular pressure, and mean and phasic coronary blood flow were monitored and recorded together with heart rate and the maximum rate of change of left ventricular systolic pressure (dP/dtmax) by using a micro1401 analog-to-digital converter [Cambridge Electronic Design (CED), Cambridge, UK] displayed on a PC and processed by using Spike2 Software (CED). The maximum rate of change of dP/dt max was used to define the timing of the cardiac cycle for segment length measurements with ultrasonic crystals. End-diastolic length was measured at the onset of the rapid increase in dP/dt max, and end-systolic length was measured at peak negative dP/dtmax. End-diastolic and end-systolic ventricular volumes were obtained from data of end-diastolic and end-systolic lengths through the specific software (Sonometrics). Percentage of segmental shortening (%SS) was calculated using the formula:
%SS ϭ (end Ϫ diastolic length Ϫ end-systolic length) ϫ 100/end-diastolic length
The data from using the Sonomicrometer crystals were digitally processed by specific hardware and software (Sonometrics). Cardiac output was derived using the Sonosoft System from data recorded by piezoelectric crystals. To calculate coronary vascular resistance, the difference between mean aortic blood pressure and mean left ventricular pressure during diastole was considered as the coronary pressure gradient. Coronary vascular resistance was calculated as the ratio between this pressure gradient and mean diastolic coronary blood flow during the steady state. At the end of the experiment, each animal was killed by an intravenous injection of 90 mg/kg pentobarbitone sodium.
Experimental protocol. The experiments were begun after at least 30 min of steady-state conditions. In the 40 pigs, the heart was paced to a frequency higher, by 20 beats/min, than that observed during the steady state, and the arterial system was connected to the pressurized reservoir. After at least 10 min of steady-state conditions, the experiments were carried out in 35 pigs by infusing either gastrin 17 (Sigma) dissolved in saline or saline only into the LAD. The infusions were completed within a period of 5 min by using an infusion pump (model 22; Harvard Apparatus) working at constant rate of 1 ml/min. The infused dose of gastrin 17 amounted to 0.005 pmol for each ml/min of measured coronary blood flow and was calculated considering the measured value of cardiac output and coronary blood flow of each animal. This dose corresponded to ϳ22 pmol/min of systemic administration and was similar to the ones that in previous studies were able to increase gastric mucosal blood flow (15, 38) . In a further five pigs, the effects of graded administration of gastrin 17 were examined by infusing the peptide at 10 subsequent doses of 0.00024, 0.001, 0.002, 0.004, 0.005, 0.007, 0.01, 0.014, 0.019, 0.024 pmol for each ml/min of measured coronary blood flow. Each dose was infused for 5 min. In 10 of the 35 pigs, when cardiovascular variables had been returned to baseline values after gastrin 17 infusion, the specific CCK1 agonist CCK33 (Bachem, Weil am Rhein, Germany; five pigs) and the specific CCK2 agonist pentagastrin (Sigma; five pigs) dissolved in saline were administered into the LAD in 5 min through the infusion pump working at 1 ml/min.
The dose of CCK33 and pentagastrin was similar to the one used for gastrin 17 and was chosen from preliminary dose-response experiments performed in the same animal model. When the cardiovascular variables had returned to control values after CCK33 and pentagastrin, these peptides were administered into the LAD in combination with gastrin 17 given at 0.005 pmol for each ml/min of measured coronary blood flow. Recordings taken for 10 min during the steady state before infusion of gastrin 17 (or CCK33 and pentagastrin alone or in co-stimulation with gastrin) at constant heart rate and aortic blood pressure were used as control. Measurements of hemodynamic variables and of coronary artery and coronary venous PO 2 and oxygen content were obtained during the last 30 s of infusion in the steady state and compared with control values. Myocardial oxygen consumption (ml O2·min Ϫ1 ·100 g Ϫ1 ) was calculated as the product of coronary sinus arterio-venous oxygen content and coronary blood flow. In the 35 pigs, the roles of muscarinic cholinoceptors and ␣-and ␤-adrenoceptors were examined throughout by repeating gastrin 17 administration at 0.005 pmol for each ml/min of measured coronary blood flow after the intravenous administration of muscarinic cholinoceptors blocker atropine sulphate (0.5 mg/kg, Sigma; five pigs), ␣-adrenoceptors blocker phentolamine (1 mg/kg, Sigma; five pigs), ␤1-adrenoceptors blocker atenolol (1 mg/kg, Sigma; five pigs), and ␤2-adrenoceptors blocker butoxamine (2.5 mg/kg, Sigma; five pigs). The involvement of the nitric oxide synthase (NOS) and of CCK1 and CCK2 receptors was examined by repeating gastrin 17 infusion after the intracoronary administration of the NOS inhibitor N-nitro-L-arginine methyl ester (L-NAME; 2 mg for each milliliter per minute of measured coronary blood flow, Sigma; five pigs), the CCK1 receptors blocker lorglumide (Sigma; five pigs), and the CCK2 receptors blocker CAM-1028 (Tocris, Bioscience, Bristol, UK; five pigs), respectively. Lorglumide and CAM-1028 were administered in the same manner using doses corresponding to 10 mg/kg and 1 mg/kg, respectively, and calculated considering the measured value of cardiac output and coronary blood flow of each animal. Similar doses of the blocking agents have been previously shown to block CCK1 and CCK2 receptors (15, 36) .
All the drugs were given in the absence of pacing of the heart and without controlling aortic pressure; their effects on baseline hemodynamic variables were measured in the steady state. Thereafter, heart rate and aortic blood pressure were kept constant, and measured hemodynamic variables were taken as "control." In all subsequent experiments, the effects of gastrin 17 in presence of blocking agents were examined while preventing changes in heart rate and aortic blood pressure. The changes of hemodynamic variables caused by various agents were compared with control values.
Finally, at the end of experiments, the expression of CCK1/2 receptors was analyzed both in fragments of myocardium and of LAD taken in each animal.
Western blotting. To analyze the expression of CCK1/2 receptors, 50 mg of each tissue sample, maintained at Ϫ80°C before being used, was washed in an ice-saline solution and lysed in an ice buffer (10 mM Tris, pH 7.4, 100 mM NaCl, 1% Triton X-100, 10 mM EDTA, 0.05% NP40), supplemented with 1:100 protease inhibitors cocktail, 1:100 sodium orthovanadate, 0.1 M sodium fluoride, and 1:1,000 phenylmethylsulfonyl fluoride (Sigma). The extracted proteins were quantified through a bicinchoninic acid protein (Pierce, Rockford, IL). For each sample, 40 g was reduced by the addition of Laemmly buffer ϫ5, resolved on 7% SDS-PAGE gels (SDS-page; Bio-Rad Laboratories, Hercules, CA), and transferred to polyvinylidene fluoride membranes (GE Healthcare, Milan, Italy), which were incubated overnight at 4°C with specific primary antibodies for CCK1 receptor (1:500, Santa-Cruz Biotechnology, Santa-Cruz, CA) and CCK2 receptor (1:500, Santa-Cruz Biotechnology). The expression of CCK1/2 receptors was normalized through ␤-actin (1:5,000, Sigma) detection.
Statistical analyses. The Student's paired t-test was used to examine changes of measured variables within each animal before and after any treatment. One-way ANOVA followed by Bonferroni post hoc tests was used to compare within each other the effects of gastrin 17, pentagastrin, and CCK33 given alone or in co-administration in different groups of animals. The non-parametric Wilcoxon SignedRank test was used to compare significance of percentage changes in hemodynamic parameters caused by gastrin 17, pentagastrin, and CCK33 and of gastrin 17 before and after blockers. Effects size r and Cohen's d have been used for analysis of changes of coronary venous PO 2, arterio-venous oxygen content, and myocardial oxygen consumption caused by gastrin 17. All data are presented as means Ϯ SD (minimum and maximum values). A value of P Ͻ 0.05 was considered statistically significant.
RESULTS
In all pigs, recordings commenced ϳ5 h after the induction of anesthesia. The mean pH, PO 2 and PCO 2 of arterial blood were 7.39 Ϯ 0.05 (7.39 -7.42), 118 Ϯ 9.5 (101-142), and 39.9 Ϯ 1 (37-42) mmHg, and the hematocrit was 38.3 Ϯ 1.3% (38 -40) .
Responses to intracoronary infusion of gastrin 17. In the 35 pigs, intracoronary infusion of the vehicle did not cause changes in the control values of hemodynamic variables. Group values of hemodynamic data caused by intracoronary infusion of gastrin 17 while preventing changes in heart rate and aortic blood pressure are shown in Table 1 .
As depicted in Fig. 1 , in each pig, intracoronary infusion of gastrin 17 caused a significant increase in mean coronary blood flow, dP/dt max , cardiac output, and %SS (P Ͻ 0.0001). The increase in coronary blood flow was accompanied by a decrease in coronary vascular resistance (P Ͻ 0.0001) and coronary venous PO 2 and increases of myocardial oxygen consumption (P Ͻ 0.0001; Table 1 The coronary and cardiac effects of gastrin 17 began within ϳ60 s after starting the infusion, reached a steady state in ϳ90 s, and were over within 5 min after the end of the infusion. Changes of right atrial pressure and left ventricular pressure were not significant (Table 1) .
Dose-response study. In the five pigs, the intracoronary infusion of the 10 doses of gastrin 17 caused a dose-response effect on coronary blood flow and cardiac function, as illustrated in Fig. 2 . The control values of mean coronary blood flow, dP/dt max , cardiac output, and %SS were 63.6 Ϯ 7.1 (55-72) ml/min, 2,021.2 Ϯ 86.2 (1,899-2,122) mmHg/s, 4,627 Ϯ 426.7 (4,002-5,090) ml/min, and 13.2 Ϯ 0.44% (12.7-13.8), respectively. The threshold dose of the hormone was found between the doses of 0.00024 and 0.001 pmol/min for each Data are means Ϯ SD (range). HR, heart rate; ABP, mean aortic blood pressure; dP/dtmax, maximum rate of change of left ventricular systolic pressure; RAP, mean right atrial pressure; LVEDP, left ventricular end-diastolic pressure; CBF, mean coronary blood flow; CVR, coronary vascular resistances; CO, cardiac output; %SS, percentage of segmental shortening; PO2vc, coronary sinus pressure of oxygen; (A-V)O2, arterio-venous sinus oxygen content; mVO2, myocardial oxygen consumption. *Significant difference vs. control (taken before gastrin 17 administration at constant HR and ABP) (P Ͻ 0.0001). ml/min. Maximal effect was observed when using the dose of 0.005 pmol/min for each ml/min.
Responses to intracoronary infusion of pentagastrin and CCK33 alone or in co-administration with gastrin 17. In the pigs that had received the CCK2 agonist pentagastrin and the CCK1 agonist CCK33, control values of heart rate and aortic blood pressure were 92.2 Ϯ 5.5 (88 -102) beats/min and 76.2 Ϯ 6.1 (69 -82) mmHg and 99.2 Ϯ 7.6 (90 -108) beats/min and 77 Ϯ 9.1 (67-87) mmHg, respectively. The infusion of the vehicles did not cause changes in hemodynamic variables.
In 10 pigs, the intracoronary pentagastrin (5 pigs) and CCK33 (5 pigs) infusion caused an increase of mean coronary blood flow of 6 Ϯ 1.2 (5-8; P Ͻ 0.0001) ml/min and of 3.6 Ϯ 1.1 (2-5; P ϭ 0.002) ml/min from control values of 65.2 Ϯ 5.4 (60 -72) ml/min and 62.2 Ϯ 9.5 (50 -71) ml/min, respectively. The coronary effects of pentagastrin and CCK33 amounted to 9.3 Ϯ 2.1% (7.1-12.7; P ϭ 0.0002) and 5.9 Ϯ 2.4% (3.7-10; P ϭ 0. , respectively. The effects of both CCK receptor agonists on coronary blood flow were significantly lower than those elicited by gastrin 17 (P Ͻ 0.0015).
In addition, the intracoronary pentagastrin infusion caused an increase of dP/dt max , %SS, and cardiac output that were similar to those elicited by gastrin 17. Also the increase of myocardial oxygen consumption from 6.87 Ϯ 0.46 (6.36 -7.41) ml O 2 ·min Ϫ1 ·100 g to 7.87 Ϯ 0.52 (7.1-8.5; P Ͻ 0.0001) ml O 2 ·min Ϫ1 ·100 g was not different from that observed during gastrin 17 infusion (15.1 Ϯ 2.6% of control values). In the pigs treated with CCK 33, no significant changes in cardiac function were observed.
The intracoronary co-administration of gastrin 17 and pentagastrin augmented the vascular and cardiac effects of both agents. The increase of coronary blood flow, dP/dt max , cardiac output, and %SS amounted to 20.6 Ϯ 3.6% (16.4 -25.9; P Ͻ 0.0001), 23.6 Ϯ 1.3% (21.9 -24.7; P Ͻ 0.0001), 24.9 Ϯ 1.5% (22.4 -26; P ϭ 0.0003), and 29.5 Ϯ 5.5% (23.5-35.7; P Ͻ 0.0001) of control values. These effects were accompanied by an increase of myocardial oxygen consumption (from 6.84 Ϯ 0.48 to 8.22 Ϯ 0.52 ml O 2 ·min Ϫ1 ·100 g; P ϭ 0.0001), which was significantly different from that caused by either gastrin 17 or pentagastrin alone.
When gastrin 17 was infused together with CCK33, only the coronary effects of both agents increased. In the five pigs, the increase of coronary blood flow amounted to 18.7 Ϯ 1.9% (15.5-20.3 ; P ϭ 0.006) of the control values and was accompanied by changes in cardiac function similar to those elicited by gastrin 17 alone. Figures 3 and 4 depict the coronary and cardiac effects of pentagastrin/CCK33 and gastrin 17 alone or in co-administration in the 10 pigs.
Changes of right atrial pressure and left ventricular pressure during pentagastrin/CCK33 and gastrin 17 infusion were not significant.
It is noteworthy that the Western blot analysis showed a stronger expression for the subtype 2 of CCK receptors in both the myocardium and LAD (Fig. 5) , which could explain the prevalence of effects of CCK2 receptor agonist over those elicited by the CCK1 receptor agonist.
Mechanisms of the responses. Tables 2 and 3 show the effects of blocking agents and of gastrin 17 given after the blocking agents on coronary blood flow and cardiac function.
As described in the tables and depicted in Fig. 6 , in the 10 pigs, blockade of muscarinic cholinoceptors (5 pigs) and ␣-ad- renoceptors (5 pigs) did not affect the coronary and cardiac responses to the intracoronary infusion of gastrin 17. Cohen's d values regarding coronary venous PO 2 , arterio-venous oxygen content, and myocardial oxygen consumption data were 0.31, 0.57, and 0.99, respectively, whereas error size r values were 0.15, 0.27, and 0.44. These analyses have shown that the effects on gastrin 17 on oxygen consumption and metabolism ranged from small to large.
In the pigs treated with ␤ 2 -adrenoceptors blocker butoxamine (five pigs) and NOS inhibitor L-NAME (five pigs), the coronary effects of intracoronary infusion of gastrin 17 were abolished in the absence of significant changes of responses of cardiac function to gastrin 17 (Tables 2 and 3; Fig. 6 ). It is also noteworthy that, after both butoxamine and L-NAME, the effects of gastrin 17 on coronary venous PO 2 and arteriovenous oxygen content turned from being a small effect into a medium to huge effect (butoxamine group: Cohen's d, 0.71 and 8.3; error size r, 0.33 and 0.97; L-NAME group: Cohen's d, 0.88 and 4.25; error size r, 0.4 and 0.9).
After the adrenoceptors blocker atenolol (five pigs) was given, the increase of coronary blood flow caused by gastrin 17 was similar to that observed before atenolol, whereas gastrin 17 failed to affect dP/dt max , cardiac output, and %SS (Table 2 ; Fig. 6 ). Also, after atenolol, the effects of gastrin 17 on coronary venous PO 2 and arterio-venous oxygen content turned from being a small effect into a medium to very large effect (Cohen's d: 1.14 and 1.42; error size r: 0.49 and 0.58). On the contrary, the effect of gastrin 17 on myocardial oxygen con- sumption turned from being a large to very large effect into a small one (Cohen's d: 0.24; error size r: 0.12).
As reported in Table 3 , blocking of CCK1 and CCK2 receptors through the CCK1 receptors blocker lorglumide and the CCK2 receptors blocker CAM-1028 caused a significant decrease of coronary blood flow (P ϭ 0.0004 and P ϭ 0.0002, respectively). Moreover, the administration of CAM-1028 reduced dP/dt max , cardiac output, and %SS (P ϭ 0.0084, P ϭ 0.0034, and P ϭ 0.0005, respectively) as well. In addition, the CCK2 antagonist completely prevented the effects of gastrin 17 on cardiac function, whereas both CCK receptors antagonists reduced the response of coronary vascular bed to gastrin 17 (Table 3 ; Fig. 6 ). After both lorglumide and CAM-1028, the effects of gastrin 17 on arterio-venous oxygen content turned from being a small effect into a medium to large effect (Cohen's d: 0.78 and 0.63; error size r: 0.36 and 0.3). In addition, with error size measurement, the changes in coronary venous PO 2 also were found to be as a small to medium effect (lorglumide group: Cohen's d: 0.32; error size r: 0.158; CAM-1028 group: Cohen's d: 0.46; error size r: 0.22). Finally, after CAM-1028, the effect of gastrin 17 on myocardial oxygen consumption turned from being a very large effect into a small effect (Cohen's d: 0.22; error size r: 0.1).
DISCUSSION
The results of this study have shown for the first time that intracoronary gastrin 17 infusion increased coronary blood flow and cardiac function through ␤-adrenergic-related pathway and the activation of CCK1 and 2 receptors. Moreover, the ␤ 2 -adrenergic-related endothelial NO release was found to play an important role in the response of coronary vascular bed to the hormone infusion.
Effects of intracoronary gastrin 17 on coronary blood flow and cardiac function. Gastrin belongs to a family of CCKrelated peptide whose members share an identical pentapeptide sequence at the biological relevant carboxyl terminal (8) . Several forms of gastrin have been identified that differ according to the number of COOH-terminal peptide residues. Gastrin 17 and gastrin 34 are the major forms found in blood and tissue, and both are released into the circulation after a meal (4) .
The results of the present study show that intracoronary gastrin 17 infusion increased coronary blood flow, dP/dt max , cardiac output, and %SS. It is noteworthy that these results were obtained by gastrin 17 infusion using similar doses to those reported to increase mucosal blood flow (15, 38) . Moreover, the infusion of such doses of gastrin 17 was found to result in plasma gastrin levels comparable to those of ϳ70 -80 ng/l that were found after a meal (3, 7, 37).
Since the experiments were performed while preventing changes in heart rate and arterial blood pressure and in the absence of changes in cardiac filling pressures, the observed responses represented primary effects of gastrin 17 on the coronary circulation and cardiac function. Furthermore, none of these responses to gastrin 17 could be obtained during intracoronary infusion of the vehicle alone given at the same rate as that of the peptide. Finally, the direct relationship between the infusion of gastrin 17 and its coronary and cardiac responses was confirmed during the dose-response study, which showed that the increase in coronary blood flow and in cardiac function could be augmented by increasing the dose of the infused substance. Therefore, the present investigation showed that intracoronary infusion of gastrin 17 primarily caused coronary vasodilation and an increase of cardiac function since this response did not involve changes in other hemodynamic variables. Moreover, since the above effects were accompanied by significant changes of myocardial oxygen consumption, the myocardial response to gastrin 17 should be considered as a direct effect of the peptide (39) . In this context, it is possible that gastrin 17 would be capable of affecting cardiac contractility by acting on ϳ49% of left ventricular mass, which is reported to be perfused by left anterior descending coronary artery in pigs (45) .
Regarding the vascular effects, the results obtained on coronary venous PO 2 , arterio-venous sinus oxygen content, and myocardial oxygen consumption caused by gastrin 17 after blocking agents administration are in support of a direct vasodilatory effect of the peptide (39) . When gastrin 17 was given after atenolol and the CCK2 receptors blocker CAM-1028, which abolished the effects of the peptide on cardiac contractility, coronary blood flow as well as coronary venous PO 2 increased and arterio-venous sinus oxygen content decreased, whereas myocardial oxygen consumption did not change. On the contrary, when gastrin 17 was infused after butoxamine and L-NAME, which abolished the vascular effects without affecting the cardiac response, the coronary venous PO 2 reduction, and the arterio-venous sinus oxygen content increase were higher than those observed in animals without the blockers. These findings on coronary oxygen content could be due to abolishing a compensatory increase of coronary blood flow to the increased myocardial oxygen consumption related to in- a P ϭ 0.0004; b P ϭ 0.0008; c P ϭ 0.016; d P ϭ 0.0011; e P ϭ 0.0022; f P Ͻ 0.0001; g P ϭ 0.0039. creased cardiac contractility. In absence of blocking agents, the effects of gastrin 17 on cardiac function would overcome the increase of coronary blood flow, which would result in a small reduction of coronary venous PO 2 and a small increase of arterio-venous sinus oxygen content. The demonstration of the above effects of gastrin 17 on the cardiovascular system is consistent with previously reported findings regarding the hemodynamic properties of other CCKrelated peptides. In rats, both CCK8 and gastrin 17 given in similar doses to those of the present study increased gastric mucosal blood flow (15, 38) . Also, the increases of renal blood flow and sodium excretion observed in dogs have been attributed to changes in circulating levels of gastrointestinal hormones such as gastrin (34) . Moreover, similar effects to those elicited by gastrin 17 have been observed in response to the infusion of the CCK2-specific agonist pentagastrin, which has been shown in rats to increase coronary blood flow and myocardial contractility (46) . Moreover, the results obtained in vitro on the gastroepiploic artery have also shown vasodilating properties of gastrin 17 (26) .
Role of autonomic nervous system and NO in the hemodynamic effects elicited by gastrin 17. In the same controlled anesthetized animal preparation, the administration of atropine, phentolamine, atenolol, and butoxamine using the same doses as the ones previously used (42, 11, 9, 43, 12) was applied to examine the involvement of muscarinic cholinoceptors and ␣-, ␤ 1 -, and ␤ 2 -adrenoceptors in the cardiovascular effects elicited by gastrin 17. Neither the blockade of muscarinic cholinoceptors nor the administration of phentolamine affected the hemodynamic responses to gastrin 17, indicating that the above effects did not involve muscarinic cholinoceptors or ␣-adrenoceptors. In contrast, the results obtained after butoxamine and atenolol administration showed the involvement of ␤-adrenoceptors in the cardiovascular effects elicited by intracoronary gastrin 17. Hence, after atenolol and butoxamine, the increases of contractility and of coronary blood flow were prevented, indicating a role played by both ␤ 1 -and ␤ 2 -adrenoceptors in the cardiac and vascular response to the hormone. It is possible that the activation of coronary ␤ 2 -adrenoceptors by gastrin 17 could balance the reflex activation of the sympathetic system caused by gastric distension and modulate the reflex reduction of coronary blood flow (40) .
The results of the present study also showed, for the first time, that, in addition to causing coronary vasodilation through ␤ 2 -adrenoceptors, gastrin 17 can increase coronary blood flow through the endothelial NO release. The regional vasodilation elicited by infusion of gastrin 17 was abolished by the local intra-arterial administration of L-NAME, which is known to inhibit the formation of NO (16) . The dose of 2 mg for 1 ml/min of measured coronary blood flow of the blocking agent used is similar to that previously shown in anesthetized pigs to abolish the vasodilation caused by intravenous infusion of 17␤-estradiol (42) and intra-arterial infusion of testosterone, genistein, and intermedin 1-47 (11, 12, 29) . The involvement of NO in the vascular effects elicited by gastrin 17 is consistent with previous reports regarding pentagastrin infusion showing that the increase of mucosal gastric blood flow was abolished or significantly reduced by L-NAME (33, 23, 28) .
Role of CCK1/2 receptors in the hemodynamic effects elicited by gastrin 17. The results obtained regarding the involvement of CCK receptors in the cardiovascular effects elicited by gastrin 17 have shown that CCK2 activation would be related to both inotropic and vasodilating effects induced by intracoronary gastrin 17 infusion, whereas CCK1 would rather be involved in the vascular action elicited by the gastrointestinal hormone. The cardiovascular effects of gastrin 17 were augmented by co-stimulation with equimolar pentagastrin, the CCK2-specific agonist (19) , whereas the co-administration of gastrin 17 and CCK33, the specific CCK1 agonist (31, 20) , increased the coronary effects of gastrin 17 only. Hence, pentagastrin intracoronary infusion caused an increase of myocardial contractility and coronary blood flow, which is in agreement with previous reports (46) . On the other hand, CCK33 intracoronary administration did not cause any significant changes in myocardial contractility and caused an increase of coronary blood flow lower than the one caused by both pentagastrin and gastrin 17. It is also noteworthy that in preliminary experiments graded intracoronary administration of CCK33 from 0.00024 to 0.024 pmol for each ml/min of measured coronary blood flow modulated only the vascular response to CCK33 without affecting cardiac function. These results are in disagreement with previous reports showing positive effects of intravenous CCK33 on cardiac function and a reduction of coronary blood flow (47) . However, those findings were accompanied by an increase of catecholamines secretion, which could have influenced the direct effects of CCK33 (47) .
The results obtained on the different role of CCK receptors in the hemodynamic effects of gastrin 17 were confirmed by experiments performed with lorglumide and CAM-1028, the selective CCK1 and CCK2 receptors antagonists, which were administered into the coronary artery in doses corresponding to the ones previously used to block CCK receptors (15, 36) . Hence, the intracoronary administration of such doses of lorglumide and CAM-1028 was able in preliminary experiments performed in anesthetized pigs to prevent the cardiovascular effects of CCK33 and pentagastrin. In pigs treated with CAM-1028, the cardiac effects of gastrin 17 were abolished and the response of coronary blood flow reduced. In contrast, the blocking of CCK1 receptors caused the reduction of the vascular effects of gastrin 17 only.
It is also noteworthy that the results obtained with CCK receptors agonists/antagonists given alone have revealed for the first time a role of CCK receptors in the modulation of coronary blood flow and cardiac function. Hence, at constant heart rate and aortic blood pressure, pentagastrin intracoronary infusion caused an increase of myocardial contractility and of coronary blood flow, which is in agreement with reports of literature (46) . In contrast, CCK33 intracoronary administration did not cause any significant change in myocardial contractility and caused an increase of coronary blood flow lower than the one caused by both pentagastrin and gastrin 17.
Moreover, using both lorglumide and CAM-1028 at constant heart rate and aortic blood pressure decreased basal coronary blood flow, whereas only CAM-1028 reduced myocardial indexes of contractility and cardiac output.
Thus these findings in the anesthetized pigs showed that both CCK receptors would be involved in the regulation of coronary vascular resistances and blood flow, whereas the CCK2 receptors only would play a role in the regulation of myocardial contractility as well. In this context, it is noteworthy that the results obtained through Western blot have shown, for the first time, the prevalence for the CCK2 receptors in the pig heart and vessels.
Hence, our results can be used to suggest a preferential activation of CCK2 receptors by gastrin 17 rather than CCK1 ones. Indeed, the CCK1 receptors have been reported to have a high affinity for CCK and sulfated CCK analogs but a low affinity for gastrin, which is a poor activator of CCK1 receptors at physiological concentrations (20, 48) . In contrast, the CCK2 receptors have been found to have almost equal affinity for gastrin and CCK as well as for desulfated CCK analogs (6, 22) . Since the CCK1 receptors have been found to be highly expressed in the myocardium rather than in the coronary vessels, it is also possible that the interaction of gastrin 17 with these receptors would not be able in the anesthetized pig to activate the intracellular pathway leading to an increase in cardiac contractility. Indeed, CCK33, the specific CCK1 agonist, failed to affect cardiac function. The results obtained through Western blot, which have shown for the first time the prevalence for the CCK2 receptors in the pig heart and vessels, would support our suggestions.
Finally, we speculate that there is a functional relationship between the CCK1/2 receptors, the ␤-adrenergic system, and NO. In particular, CCK2 receptor-related signaling and ␤ 1 -adrenergic pathways could interact with each other in eliciting the increase of cardiac contractility. In contrast, both CCK1/2 receptors and ␤ 2 -adrenergic pathways could work together in causing coronary vasodilation through modulation of NO release. Indeed, preliminary results obtained from in vitro studies seem to support the existence of such relationships regarding the specific intracellular signaling.
In conclusion, the results of this study have shown that gastrin 17 may modulate the cardiovascular responses reflexly caused by gastric distension through the activation of the CCK receptors, the ␤-adrenergic system, and NO. Thus the vasodilation caused by gastrin 17 would not be related to only sympathoinhibitory effects on central nervous system as reported for other gastrointestinal peptides (34) but to a local modulation of NO release regulated by the ␤-adrenergic system.
Limitations
Since a high-fidelity micro-tipped pressure transducer was not used for measuring dP/dt max , the reported data on peak dP/dt max were not accurate; the use of a fluid-filled catheter loses much of the high-frequency components of pressure waves. However, for the purpose of our study, measuring dP/dt max has been useful for timing the cardiac cycle when determining segment length obtained by ultrasonic crystals.
